Jump to navigation Jump to content

Frontpage News 2012 Diabetes treatment for children

CZ0100_IMG4.bmp

Diabetes treatment for Czech children

  • The treatment of children with monogenic diabetes in the Czech Republic will be significantly improved with support from the Norway Grants.

    Monogenic diabetes is a special hereditary form of diabetes, less well known than type 1 and 2. Approximately five percent of diabetes patients in the Czech Republic suffer from this version of the illness, which is normally much easier to treat than other diabetes forms. Backed by a €0.5 million grant from Norway, the University Hospital Motol has purchased laboratory equipment to strengthen the hospital's capacity to treat this patient group.

    This form of diabetes is caused by a disorder of a genome, which needs to be identified for the disease to be treated adequately. The grant has been used to acquire equipment that analyses the genomes in order to detect the one genome causing the disease. Prior to the installation of the new equipment, the hospital was only able to test a few patients each week, resulting in long waiting periods and delays in the treatment of children afflicted with the disease. The hospital can now test and administer treatment to a much larger number of patients. In addition to the new equipment, the support will finance the operation of the laboratory for two years.

    Monogenic diabetes can in many cases be treated with tablets, rather than the more cumbersome insulin injections that are common for other types of diabetes. The correct diagnostication of the disease will therefore provide a greater quality of life for patients.

    The staff of the University Hospital Motol in Prague has great experience with testing and treating diabetes, and is aided in this task by partnerships with health research institutions in Denmark, Norway and Great Britain. Among these are the National Institute of Public Health in Oslo, which has already been involved in cooperation with the Czech hospital for 11 years. The current project at the hospital further develops the collaboration and strengthens the common efforts to prevent and treat diabetes.

  • Country:

    Czech Republic


    Project title:

    Monogenic diabetes in children: from genetics to therapy.

    Case number:

    CZ0100

    Priority sector:

    Health and childcare

    Grant:

    € 443,259

    Status:

    Concluded

    Type & project assistance:

    Individual Project

    Project promoter:

    University Hospital Motol

    Type of institution:

    Individual project

    Project website:

    www.fnmotol.cz

    Project duration:

    31 months

    Project cost:

    € 522,280

    Grant rate:

    85%

    Grant from:

    Norway Grants

    Grant agreement date:

    16 September 2008

    The purpose of the Project is to purchase equipment for the University Hospital in Motol, and carry out genetic testing and counseling of children with monogenic forms of childhood diabetes, with the overall objective of finding improved methods of treatment for children with monogenic diabetes. Reference is made to the application dated 3 January, 2008 and to any subsequent correspondence with the Focal Point.



    The completed Project shall include the following activities and results:

    - public tender and purchase of the instruments for genetic testing;

    - instrumentation testing and preparation of the hospital unit for the testing period of approximately two years;

    - carrying out the actual testing over a period of 22 months; preparing and sharing the results; and publication of the results in scientific journals;

    - management and publicity



    The Project Promoter is the University Hospital Motol.



    Subject to national law, the Project shall be implemented in partnership with three institutions: (1) the National Institute of Public Health, Oslo; (2) the Steno Diabetes Centre, Gentofte, Denmark; (3) the Peninsula Medical School, Exeter, U.K.



    The Focal Point shall ensure that the Project Promoter covers at least 15.13 percent of the total eligible Project costs.